Concepedia

Author

Mafalda Ramos

Boehringer Ingelheim (Germany)ORCID

Also Known As

M. Ramos, MAFALDA RAMOS, Mafalda C Ramos, Mafalda C. Ramos, Mafalda Ramos, Ramos, Mafalda C

33

Publications

293

Citations

11

H-Index

11

Concepts

All Affiliations

Boehringer Ingelheim (Germany)Boehringer Ingelheim (United Kingdom)Aalborg UniversityBoehringer Ingelheim (Denmark)Peking University
MR

About

Mafalda Ramos is an author at Boehringer Ingelheim (Germany) specializing in public health, health sciences, and metabolic syndrome.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

2

2

75

2

Public Health

2

2

75

3

Diabetes

2

2

75

4

Medicine

1

1

42

5

Global Health

1

1

33

Mafalda Ramos

×

12

Publications

264

Citations

11

H-Index

YearCitations

Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients

G Goodall, Mark Lamotte, Mafalda Ramos,

Journal of Medical Economics

2018

43

Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge

Lei Si, Michael Willis, Christian Asseburg,

Value in Health

2020

42

Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease

Mafalda Ramos, V. Foos, Anastasia Ustyugova,

Diabetes Therapy

2019

36

Assessing the Burden of Type 2 Diabetes in China Considering the Current Status-Quo Management and Implications of Improved Management Using a Modeling Approach

V. Foos, Ke Wang, Phil McEwan,

Value in Health Regional Issues

2018

33

Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK

Mafalda Ramos, Michael H. Cummings, Anastasia Ustyugova,

Diabetes Therapy

2020

24

Multicenter Prospective Evaluation of Parenteral Nutrition Preparation Time and Resource Utilization: 3‐Chamber Bags Compared With Hospital Pharmacy–Compounded Bags

Sarah V. Cogle, Robert G. Martindale, Mafalda Ramos,

Journal of Parenteral and Enteral Nutrition

2020

14

Cost–effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes

Mafalda Ramos, Anastasia Ustyugova, N. Hau,

Journal of Comparative Effectiveness Research

2020

13

Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy

Rory J. McCrimmon, Mark Lamotte, Mafalda Ramos,

Diabetes Therapy

2021

13

Cost-effectiveness of the tubeless automated insulin delivery system vs standard of care in the management of type 1 diabetes in the United States

Joseph Biskupiak, Mafalda Ramos, Carol J. Levy,

Journal of Managed Care & Specialty Pharmacy

2023

13

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China

Mafalda Ramos, Peng Men, Xu Wang,

Cost Effectiveness and Resource Allocation

2021

12

Page 1